DavidRDrosickMD

PubMed

• Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.
  David M Waterhouse, Patrick Ward, David R Drosick, Caleb Burdette, Daniel Davies, Molly A Mendenhall> ;JCO Oncology Practice. 2023 Nov 1
• Integration of Genetic Testing and Counseling in Patients With Breast Cancer in a Large, Multisite Community-Based Practice.
  Molly A Mendenhall, Andrew Guinigundo, Dan Davies, Patrick Ward, David R Drosick, David M Waterhouse> ;JCO Oncology Practice. 2024 Feb 1
• 1 citations
  Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non-Small-Cell Lung Cancer in a Large Community Oncology Practice.
  David M Waterhouse, Patrick Ward, Suzzette Arnal, Marcus Neubauer, David R Drosick, Dan Davies, Molly A Mendenhall> ;JCO Oncology Practice. 2023 Jun 1
• 17 citations
  TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
  Denise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, Janice F. Eakle, Adam Brufsky, David Drosick, Fred J. Kudrik, Linda D. Bosserman, Mark Keaton, Sharon A. Goble,...> ;Breast Cancer Research and Treatment. 2017 May 15
• 10 citations
  Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
  Denise A. Yardley, Natalie R. Dickson, David Drosick, Chris Earwood, Roger Inhorn, Patrick B. Murphy, John D. Hainsworth> ;Clinical Breast Cancer. 2016 Jun 1
• Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
  Yardley, D. A.,Hart, L.,Waterhouse, D.,Whorf, R.,Drosick, D. R.,Murphy, P.,Badarinath, S.,Daniel, B. R.,Childs, B. H.,Burris, H.> ;Breast Cancer Res. Treat.. 2013 Nov 21
• TITAN: Ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): Preliminary toxi...
  Yardley DA, Hainsworth JD, Harwin WN, Goble SA, Daniel BR, Ackerman MA, Shipley D, Drosick DR, Hanson SE, Griner PL, Burris HA> ;J. Clin. Oncol.. 2011-05-20
• Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC).
  Borson R, Harker WG, Reeves JE, Drosick D, Beck JT, Hager SJ, Horvath WL, Bromund J, Zeigler H, Tai D, Yardley DA> ;J. Clin. Oncol.. 2011-05-20
• 28 citations
  A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
  Denise A. Yardley, Howard A. Burris, L. Simons, David R. Spigel, F. Anthony Greco, J. H. Barton, Dianna Shipley, David Drosick, John D. Hainsworth> ;Clinical Breast Cancer. 2008 Oct 1
• A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.
  Yardley, D. A., Daniel, D., Stipanov, M., Drosick, D. R., Mainwaring, M., Peyton, J., Shastry, M., Hainsworth, J. D.> ;Cancer Invest. 2010 Oct
• Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival.
  Lower, E. E., Drosick, D. R., Blau, R., Brennan, L., Danneman, W., Hawley, D. K.> ;Clin Breast Cancer. 2003 Jun
• Join now to see all